ArticleFrontiers in cardiovascular medicine2025
Direct current cardioversion of atrial fibrillation in patients with left atrial appendage occlusion devices.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined Direct Current Cardioversion and Left Atrial Appendage Occlusion in Patients With Contraindication to Anticoagulation: A Single-Center Feasibility Study.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Data on the safety of direct current cardioversion (DCCV) in patients with left atrial appendage occlusion (LAAO) devices and its impact on thromboembolic prevention are limited. This study aimed to investigate the safety and efficacy of DCCV in patients with LAAO devices. Methods: This single-center, ambispective cohort included patients undergoing one-stop procedures [LAAO combined with radiofrequency catheter ablation (RFCA)], where LAAO was performed first. DCCV was performed to restore sinus rhythm after LAAO. Patients were divided into the DCCV group and the no-DCCV group. Safety endpoints included DCCV-related death, device dislodgment, device embolization, and major bleeding events. Efficacy endpoints contained all-cause death, cardiovascular death, stroke/transient ischemic attack, and systemic embolism. Results: A total of 196 patients (age 72.5 ± 7.4 years, 51.0% male) were enrolled, with 95 patients undergoing DCCV after LAAO. No DCCV-related death, device dislodgement, or device embolism was observed. At 12 months, the safety endpoints occurred in 3.2% of the DCCV group vs. 6.9% of the no-DCCV group ( Conclusions: No signal of excess risk was observed when performing DCCV in patients with LAAO devices. Tiny changes in device diameter after DCCV were noted on TEE at 45° and 90°, but these were not associated with adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.